FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| | | | _ |
|-------------|------|-------|---|
| Vashington, | D.C. | 20549 | |

| STATEMENT | OF CHANG | ES IN BENEF | ICIAL | OWNERSH | ΙP |
|-----------|----------|-------------|-------|---------|----|
| | | | | | |

| OMB APPROVAL | | | | | | | | |
|--------------------------|-----|--|--|--|--|--|--|--|
| OMB Number: 3235-0287 | | | | | | | | |
| Estimated average burden | | | | | | | | |
| hours per response: | 0.5 | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* Reasons Bryan M. | | | | | 2. Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ACRS] | | | | | | (Che | Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | | | | | | |
|--|--|---|-----------------------------------|--------------------|---|---------|--|-----------------|----------------------|---|-----------------|---|--|--|--------------------|--------|--------|-------|----|---|--|
| | ` | First) ERAPEUTICS, I JITE 200 | (Middle) | (| 3. Date of Earliest Transaction (Month/Day/Year) 06/04/2020 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | Officer (below) | give title | Filing / | Other (s below) | pecify | | | | | |
| (Street) WAYNE (City) | | A State) | 19087 | | 4. II Ameriument, Date of Original Filed (Month/Day/Year) | | | | | Line) | Form file | ridual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | | | | |
| | | | able I - Non- | Derivat | tive S | ecuriti | es Aca | uired. | Disi | nosed of. | or Bene | eficially | Owned | | | | | | | | |
| 1. Title of Security (Instr. 3) | | 2. Transact Date Month/Day | action 2A. Deemed Execution Date, | | 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a | | (A) or | 5. Amount of | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership | | | | | | | | | |
| | | | | Code V Amount (A | | | | | (A) or (D) | Price | Transactio | | | | (Instr. 4) | | | | | | |
| Common | Stock | | | 06/06/2020 M 7,333 | | | | A | (1) | 16,209 | | | D | | | | | | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | Conversion Date Execution Date, or Exercise (Month/Day/Year) if any (Month/Day/Year) 8 Perivative | | Code | saction e (Instr. Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Ar of Securities Underlying Derivative Sec (Instr. 3 and 4) | | ies g Security | Derivative Security curity (Instr. 5) | | er of e s ally | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) | | | | | | | |
| | | | | Code | v | (A) | (D) | Date Exercis | sable | Expiration Date | Title | Amount or Number of Shares | | Reported Transaction(s) (Instr. 4) | | | | | | | |
| Option Grant (right to buy) | \$1.41 | 06/04/2020 | | A | | 16,500 | | (2) | | (2) | | (2) | | 06/03/2030 | Common Stock | 16,500 | \$0.00 | 16,50 | 00 | D | |
| Restricted Stock Units | (1) | 06/06/2020 | | М | | | 7,333 ⁽³⁾ | (4) | | (4) | Common Stock | 7,333 | \$0.00 | 0 | | D | | | | | |

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- 2. The shares subject this option will vest in twelve equal monthly installments commencing July 4, 2020, subject to Reporting Person's continuous service through each such date.
- 3. This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy.
- 4. The shares underlying these restricted stock units vested on June 6, 2020.

Remarks:

/s/ Mark Ballantyne, Attorney-06/08/2020 in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.